Beigene Appoints Shalini Sharp to Board

By Tamara Parker • Thursday, September 26 15:18 • Permanent Link

Beigene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, recently announced the appointment of Shalini Sharp to its board of directors, effective September 27, 2024. Sharp brings extensive experience in leading innovative global pharmaceutical companies and currently serves as a board member of Neurocrine Biosciences and Organon & Co. Prior to joining Beigene's board, she held notable positions at Ultragenyx, Elan Pharmaceuticals, and Goldman Sachs.

Beigene's commitment to innovation and making cancer treatments more accessible has resonated with Sharp, who expressed excitement about joining the board at a time of rapid global growth for the company. With a growing global team of more than 10,000 colleagues spanning five continents, Beigene is focused on developing innovative treatments and improving access to medicines for cancer patients worldwide.

The full board of directors list is available on the Beigene website. For more information about Beigene, visit www.beigene.com and follow the company on LinkedIn, X (formerly known as Twitter), Facebook, and Instagram. Today the company's shares have moved 3.4% to a price of $213.76. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.